At Imidazole Ring Carbon Patents (Class 514/400)
  • Patent number: 11939375
    Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: March 26, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Jacqueline Benson, Jill Carton, Mark Cunningham, Yevgeniya Orlovsky, Robert Rauchenberger, Raymond Sweet
  • Patent number: 11883383
    Abstract: The present invention relates to pharmaceutically acceptable salts of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethylamine (“COMPOUND I”) useful in the treatment of RAGE mediated diseases.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: January 30, 2024
    Assignee: VTV THERAPEUTICS LLC
    Inventor: Juan Hu
  • Patent number: 11872221
    Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an untreated or treatment-resistant diabetes with a glucokinase activator, optionally in combination with a dipeptidyl peptidase-4 inhibitor.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: January 16, 2024
    Assignee: HUA Medicine (Shanghai) Ltd.
    Inventors: Li Chen, Shuang Ren, Jiayi Zhang
  • Patent number: 11857536
    Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a glucokinase-mediated disorder, disease, or condition in a renally impaired subject with a glucokinase activator (GKA), for example, dorzagliatin. Also provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a diabetes in a renally impaired subject with a GKA. Additionally, provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a chronic kidney disease with a GKA.
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: January 2, 2024
    Assignee: HUA Medicine (Shanghai) Ltd.
    Inventors: Li Chen, Shuang Ren, Chengfeng Jiao, Yaohui Wang
  • Patent number: 11844780
    Abstract: The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.
    Type: Grant
    Filed: April 17, 2023
    Date of Patent: December 19, 2023
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Kristin Patterson, Mark Hatcher
  • Patent number: 11812746
    Abstract: A method of controlling a fungus infection in a plant susceptible to Botrytis infection is provided. The method comprising applying to the plant an effective amount of a phenylalanine or an analog thereof for controlling said fungus infection in the plant.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: November 14, 2023
    Assignee: THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER)
    Inventors: Michal Oren-Shamir, Moran Oliva, Efraim Lewinsohn, Noam Alkan, Yigal Elad
  • Patent number: 11752134
    Abstract: Compositions containing one or more amino acids selected from the group consisting of 25 mol % to 45 mol % of leucine, and 20 mol % to 40 mol % of phenylalanine relative to the total content of leucine, lysine, valine, isoleucine, phenylalanine, histidine, and tryptophan, are useful for improving cognitive function, for improving anxiety-like symptoms, and for suppressing cerebral atrophy and are highly safe and can be ingested or administered continuously.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: September 12, 2023
    Assignee: AJINOMOTO CO., INC.
    Inventors: Hideaki Sato, Masako Yasui, Yusuke Adachi, Katsuya Suzuki, Michihiro Takada
  • Patent number: 11746097
    Abstract: In some aspects, the present disclosure provides compounds of the formula: (I) or (II) wherein the variables are as defined herein. In some embodiments, these compounds may be used to treat cancer or other hyperproliferative diseases, as well as atherosclerosis and coronary artery disease.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: September 5, 2023
    Assignee: Saint Louis University
    Inventors: Thomas Burris, John K. Walker, Colin Flaveny, Arindam Chatterjee
  • Patent number: 11723979
    Abstract: The present invention includes compositions and methods for providing a therapeutically acceptable dose of an active pharmaceutical agent for once a day delivery of the active pharmaceutical compound in an amount effective to treat at least one of: Sjogren's syndrome, Xerostomia, dry mouth, hypo-salivation, or dental carries due to reduced or compromised salivation, wherein both the peak and trough times in the blood level at 8 hours is greater than 25% of the peak value in the blood level concentration.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: August 15, 2023
    Assignee: Spectrix Therapeutics, LLC
    Inventor: Mark Tengler
  • Patent number: 11654115
    Abstract: According to the invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: May 23, 2023
    Assignee: VICORE PHARMA AB
    Inventors: Ola Camber, Christina Johansson
  • Patent number: 11633354
    Abstract: The disclosure is directed to methods related to creatinine, for example, a method for its safe administration to a human, a method for using creatinine to improve the bioavailability of creatine, and a metn.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: April 25, 2023
    Assignee: THERMOLIFE INTERNATIONAL, LLC
    Inventors: Alexandros Nikolaidis, Ronald Kramer
  • Patent number: 11634428
    Abstract: The present invention is concerned with novel deuterated Angiotensin-Converting Enzyme-2 (ACE-2) inhibitors of general structural formula I, their optically active enantiomers and diastereoisomers, and pharmaceutical salts and compositions thereof, as well as combination therapies which include compounds of the present invention, These compounds have high potency and selectivity for Angiotensin-Converting Enzyme-2 (ACE-2) inhibition, and are useful in the treatment of infectious respiratory diseases including the pandemic disease Covid-19, Severe Acute Respiratory Syndrome (SARS-CoV-2), Severe Acute Respiratory Syndrome (SARS-CoV), and other diseases caused by coronaviruses.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: April 25, 2023
    Inventor: Daljit Singh Dhanoa
  • Patent number: 11597717
    Abstract: Provided are compounds of Formula Y-Z: The compounds target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: March 7, 2023
    Assignee: Landos Biopharma, Inc.
    Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
  • Patent number: 11564941
    Abstract: In one embodiment, a composition is provided, comprising: 0.0005 wt % to 0.05 wt % of silver nitrate, based on a total weight of the composition; 0.01 wt % to 1.0 wt % of hyaluronic acid, based on the total weight of the composition; and 0.05 wt % to 2.5 wt % of allantoin, based on the total weight of the composition. In one embodiment, a method of treating a skin wound is provided, comprising: topically applying a sufficient amount of a composition to the skin wound of a patient to cover the skin wound, the composition comprising: 0.0005 wt % to 0.05 wt % of silver nitrate, based on a total weight of the composition; 0.01 wt % to 0.1 wt % of hyaluronic acid, based on the total weight of the composition; and 0.05 wt % to 2.5 wt % of allantoin, based on the total weight of the composition.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: January 31, 2023
    Inventor: Brian Brazzo
  • Patent number: 11534377
    Abstract: The present invention is directed to a hair growth agent for external use comprising chiro-inositol, which is provided as an excellent hair growth agent.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: December 27, 2022
    Assignee: KOBAYASHI PHARMACEUTICAL CO., LTD.
    Inventors: Kosuke Tanaka, Mihoko Kawasaki, Hironori Tomi, Takashi Tsuji
  • Patent number: 11389387
    Abstract: The subject of the application is protein hydrolyzates having specific amounts of the amino acids arginine and lysine, which demonstrate improved properties in hair treatment compositions and in cleansing compositions for skin and hair, and also enzymatic methods for the preparation thereof, and the cosmetic compositions comprising same.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: July 19, 2022
    Assignee: BASF SE
    Inventors: Hans-Martin Haake, Christina Kohlmann, Christian Markiefka, Guadalupe Pellon, Ansgar Behler
  • Patent number: 11253496
    Abstract: Provided herein are nutritional, or therapeutic, compositions and methods of use in primarily treating kidney patients suffering from low serum albumin. The compositions are divided into four formulations, comprising: 1) the magnesium salt and/or the calcium salt of the alpha keto acids of: ?-leucine, ?-valine, ?-isoleucine, ?-phenylalanine, ?-hydroxy methionine; and/or ?-tryptophan, and/or ?-tyrosine; 2) L-lysine monoacetate, L-threonine; and/or 3) histidine, tryptophan, and tyrosine, as amino acids or base acids. The specific formulation administered depends in part upon which stage 2-5 of renal disease the patient has. The invention further comprises methods of treatment of disorders associated with low serum albumin using the composition as an over-the-counter pill. The patient's serum albumin is tested on a periodic basis and the selected composition and dose are adjusted accordingly.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: February 22, 2022
    Inventor: Edgar L. Hull, Jr.
  • Patent number: 11224582
    Abstract: Amino acid formulations for pancreatic vitality. The formulations comprise a mixture of a plurality of amino acids, wherein the mixture comprises at least one amino acid selected from the group consisting of serine, glutamic acid, and/or carnitine. Methods of enhancing pancreatic vitality, stabilizing blood glucose levels, and improving A1C levels in subjects in need thereof are also described.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: January 18, 2022
    Assignee: Almeda Labs LLC
    Inventors: Stacy Tucker, Sushrutha Nagaraj
  • Patent number: 11104632
    Abstract: Vanillin derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: August 31, 2021
    Assignee: King Abdulaziz University
    Inventors: Abdelsattar Mansour Ebeid Omar, Moustafa El-Sayed El-Araby, Martin K. Safo
  • Patent number: 11007164
    Abstract: Compositions containing one or more kinds of essential amino acids other than leucine and not less than 35 mol % of leucine, relative to the total content of essential amino acids, are useful for preventing or improving dementia or a depressive state, in particular, a depressive state caused by stress, have high safety, and can be continuously ingested or administered.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: May 18, 2021
    Assignee: AJINOMOTO CO., INC.
    Inventor: Shinobu Nishitani
  • Patent number: 10959987
    Abstract: Imidazole-based compounds as hepatitis C virus (HCV) inhibitors. The compounds have an imidazole core that is disubstituted via amide links. Also described are a pharmaceutical composition incorporating the imidazole-based compound, a method of preparing these compounds, and a method for using the pharmaceutical composition in the treatment of HCV infection.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: March 30, 2021
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar Mansour Omar, Mahmoud Abdelkhalek El-Faky, Sameh Hamdy Abdelmageed Soror, Maan Talaat Khayat, Hani Zakariah Asfour, Faida Hassan Bamane
  • Patent number: 10898456
    Abstract: Ingesting an agent containing cystine or a salt thereof, as an active ingredient, is effective for improving exercise-induced gastrointestinal disorder, providing an improvement effect equal to or better than that by the conventional technology on exercise-induced gastrointestinal disorders including exercise-induced decline in gastrointestinal tract barrier function.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: January 26, 2021
    Assignee: AJINOMOTO CO., INC.
    Inventors: Yoshihito Nogusa, Ami Mizugaki
  • Patent number: 10881629
    Abstract: Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: January 5, 2021
    Assignee: Natural Alternatives International, Inc.
    Inventors: Roger Harris, Mark Dunnett
  • Patent number: 10821096
    Abstract: Imidazole-based compounds as hepatitis C virus (HCV) inhibitors. The compounds have an imidazole core that is disubstituted via amide links. Also described are a pharmaceutical composition incorporating the imidazole-based compound, a method of preparing these compounds, and a method for using the pharmaceutical composition in the treatment of HCV infection.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: November 3, 2020
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar Mansour Omar, Mahmoud Abdelkhalek El-Faky, Sameh Hamdy Abdelmageed Soror, Maan Talaat Khayat, Hani Zakariah Asfour, Faida Hassan Bamane
  • Patent number: 10550089
    Abstract: The present application relates to certain substituted imidazole and triazole compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating pain, musculoskeletal inflammation, neuroinflammatory disorders, airway inflammation, itch, dermatitis, colitis and related conditions. The compounds are of Formula (I) where X is N or CH, Z and Y are N or C (but both not N) and R1-R3 are as defined herein.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: February 4, 2020
    Assignee: Heptares Therapeutics Limited
    Inventors: John Graham Cumming, Frank Xinhe Wu, Karl Henrik Edman, Hongming Chen, Dean Gordon Brown, Roland Werner Burli, Shawn Donald Johnstone, Giles Albert Brown, Benjamin Gerald Tehan, Barry John Teobald, Miles Stuart Congreve
  • Patent number: 10435376
    Abstract: Disclosed are derivatives of 1H-imidazole-4,5-dicarboxamide and use thereof in preparation of anticoccidial drugs. The derivatives have structural formulae as shown in formulae (I) to (VI). The derivatives of 1H-imidazole-4,5-dicarboxamide as disclosed in the present invention have significant anticoccidial effect, especially against coccidia that show a resistance to other anticoccidial drugs, and thus they can be used in preparation of anticoccidial drug.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: October 8, 2019
    Assignee: GUANGZHOU INSIGHTER BIOTECHNOLOGY CO., LTD.
    Inventors: Xianfeng Peng, Zonghua Qin
  • Patent number: 10390553
    Abstract: Ingesting a food etc. which is in a unit package form per meal and contains, in the unit, not less than 0.3 g of histidine as an ingestion amount per meal is effective for improving mental energy and biorhythm.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: August 27, 2019
    Assignee: AJINOMOTO CO., INC.
    Inventors: Tetsuro Shibakusa, Mayu Sugita, Ikuko Sasahara, Naoto Koyama, Shinobu Seki
  • Patent number: 10342826
    Abstract: The present invention concerns the use of a combination consisting of D-aspartic and L-aspartic acids or L-aspartic acid used alone to stimulate the procreative activity in the man by increment of spermatozoon number and motility.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: July 9, 2019
    Assignee: MERCK SERONO S.P.A.
    Inventors: Salvatore D'Aniello, Enrico D'Aniello
  • Patent number: 10028935
    Abstract: Disclosed are novel stable compounds having anti-oxidant properties and methods of using the compounds for the treatment of diseases or injuries associated with oxidative stress.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: July 24, 2018
    Assignee: XPD Holdings, LLC
    Inventors: Marc Bailie, Steven K. Duddy, Jim Herman
  • Patent number: 9931371
    Abstract: A method and a pharmaceutical composition for increasing wound healing in an individual in need thereof, the method comprising administering an angiopoietin like 4 (ANGPTL4) polypeptide or a therapeutically active fragment thereof.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: April 3, 2018
    Assignee: Nanyang Technologies University
    Inventors: Nguan Soon Tan, Han Chung Kelvin Chong
  • Patent number: 9907770
    Abstract: Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: March 6, 2018
    Assignee: Natural Alternatives International, Inc.
    Inventors: Roger Harris, Mark Dunnett
  • Patent number: 9895344
    Abstract: Novel compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of 7,8-dihydroxyflavone or derivative thereof. Specifically, methods and compounds for the treatment of disorders including neurologic disorders, neuropsychiatric disorders, and metabolic disorders (e.g., obesity) are provided. For example, a first method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes selecting a subject with or at risk of developing depression, anxiety, or obesity, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof. A further method of promoting neuroprotection in a subject also is provided, which includes selecting a subject in need of neuroprotection, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: February 20, 2018
    Assignee: EMORY UNIVERSITY
    Inventor: Keqiang Ye
  • Patent number: 9808444
    Abstract: Several embodiments provided herein relate to histamine dosing regimens are and uses of such regimens in the restoration of histamine balance in subjects suffering from, for example, histapenia and/or histadelia. Several embodiments also relate to the use of histamine dosing regimens for the treatment and/or prevention of migraine headaches.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: November 7, 2017
    Assignee: BioHealthonomics Inc.
    Inventor: Cristian Arnou
  • Patent number: 9789125
    Abstract: The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 17, 2017
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Luigi Anzalone, Frank J. Villani, Christopher A. Teleha, Penina Feibush, Barry Fegely
  • Patent number: 9700548
    Abstract: The present invention provides combinations comprising a sedating antihistamine and selected indole-based natural products such as L-tryptophan, 5-hydroxytryptophan and melatonin, along with pharmaceutically acceptable calcium and magnesium salts and selected B vitamins. These combinations are useful in providing a medicament for improving sleep in mammals, especially humans.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: July 11, 2017
    Assignee: REQUIS PHARMACEUTICALS INC.
    Inventors: Lars Jacob Stray Knutsen, Judi Lois Knutsen
  • Patent number: 9669010
    Abstract: A method of treating chronic kidney disease by administering to a subject a composition that includes L-arginine, glycine, L-glutamine, L-histidine, L-aspartic acid L-glutamic acid, and L-carnosine.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: June 6, 2017
    Assignee: Bio Health Solutions, LLC
    Inventor: James Archer
  • Patent number: 9668994
    Abstract: Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: June 6, 2017
    Assignee: Natural Alternatives International, Inc.
    Inventors: Roger Harris, Mark Dunnett
  • Patent number: 9629800
    Abstract: The present invention concerns gastroretentive formulation comprising an active substance granulated with a mixture of a weak gelling agent, a strong gelling agent, and a gas generating agent and process for manufacturing said formulation.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: April 25, 2017
    Assignee: ETHYPHARM
    Inventors: Mahendra Chaudhari, Omprakash D. Chandwani, Rajashree S. Yelegaonkar
  • Patent number: 9539278
    Abstract: It has been found that high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, especially in relative absence of glutamate equivalents, improve the metabolism of ketobodies and/or lactate in a mammal's body, especially in diseased or traumatic conditions. As a result, levels of ketobodies and lactate can be decreased and unphysicologically high acidity normalised. Thus, it is an object of the invention to provide an enteral nutritional or a pharmaceutical composition for the treatment and/or prevention of disturbed ketone and lactate metabolism, i.e. elevated concentrations of ketone bodies, lactate and/or other organic acids and/or insufficient pH homeostasis, especially elevated concentrations of ketone bodies and/or lactate, in a mammal's blood, wherein the composition comprises high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, preferably in relative absence of glutamate equivalents.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: January 10, 2017
    Assignee: N.V. Nutricia
    Inventor: Robert Johan Joseph Hageman
  • Patent number: 9511054
    Abstract: Several embodiments provided herein relate to histamine dosing regimens are and uses of such regimens in the restoration of histamine balance in subjects suffering from, for example, histapenia and/or histadelia. Several embodiments also relate to the use of histamine dosing regimens for the treatment and/or prevention of migraine headaches.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: December 6, 2016
    Assignee: BioHealthonomics Inc.
    Inventor: Cristian Arnou
  • Patent number: 9504673
    Abstract: The invention relates to an agent for the treatment and/or prophylaxis of highly pathogenic infectious diseases, such as highly pathogenic influenza A (in particular, subtypes H5 and H7) and severe acute respirator syndrome caused by the genotype IV coronavirus. The agent is in the form of glutaryl histamine or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition based on glutaryl histamine or a pharmaceutically acceptable salt thereof and to a method for the treatment and/or prophylaxis of highly pathogenic infectious diseases.
    Type: Grant
    Filed: May 10, 2010
    Date of Patent: November 29, 2016
    Assignee: LTD “Valenta-Intellekt”
    Inventors: Vladimir Evgenievich Nebolsin, Galina Alexandrovna Zheltukhina, Sergey Vladimirovich Borisevich, Svetlana Yakovlevna Loginova, Alexander Grigorievich Chuchalin
  • Patent number: 9500660
    Abstract: The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to a new biomarker, its use and a method that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to be susceptible to a diet induced weight gain. For example, the biomarker may be isovalerylglycine.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: November 22, 2016
    Assignee: Nestec S.A.
    Inventors: Francois-Pierre Martin, Claire L. Boulange, Ivan Montoliu Rora, Sebastiano Collino, Marc-Emmanuel Dumas, Elaine Holmes, Serge Andre Dominique Rezzi, Jeremy Nicholson, Sunil Kochhar
  • Patent number: 9480669
    Abstract: Disclosed is a method comprising the administration of a 3% amino acid and 3% glycerin solution for the use of prevention and disruption of bacterial biofilms. Also disclosed is method comprising the administration of L-cysteine 0.4 g per 100 ml for the prevention and destruction of fungal biofilms.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: November 1, 2016
    Assignee: The Regents of The University of California
    Inventors: Thomas Benedict Bryan, Clarissa J. Nobile
  • Patent number: 9447112
    Abstract: The present invention provides compounds of the formula (I) wherein: X1, X2 and X3 are heteroatoms; R4, R5, R6, R7, R8, R9 and R10 are independently selected from H, halo, —OH, —NO2, —CN and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; and Z is optionally substituted C1-8 straight-chained or branched aliphatic, optionally containing 1 or more double or triple bonds, wherein one or more carbons are optionally replaced by R* wherein R* is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino acid residue, H, —CN, —C(O)—, —C(O)C(O)—, —C(O)NR1—, —C(O)NR1NR2—, —C(O)O—, —OC(O)—, —NR1CO2—, —O—, —NR1C(O)NR2—, —OC(O)NR1—, —NR1NR2—, —NR1C(O)—, —S—, —SO—, —SO2—, —NR1—, —SO2NR1—, —NR1R2, or —NR1SO2—, wherein R1 and R2 are independently selected from H and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or where R* is NR1R2, R1 and R2 optionally together with the nitrogen atom form an optionally substituted 5-12 me
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: September 20, 2016
    Assignee: University of Kentucky
    Inventors: Peter A. Crooks, Craig T. Jordan, Xiaochen Wei
  • Patent number: 9421267
    Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: August 23, 2016
    Assignee: NeuroDerm, Ltd.
    Inventors: Oron Yacoby-Zeevi, Mara Nemas
  • Patent number: 9364489
    Abstract: The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: June 14, 2016
    Assignee: Forest Tosara Limited
    Inventors: Luigi Anzalone, Frank J. Villani, Christopher A. Teleha, Penina Feibush, Barry Fegely
  • Patent number: 9351960
    Abstract: The invention relates to medicine and comprises an agent for the treatment of a viral hepatitis C, which is glutaryl histamine or a pharmaceutically acceptable salt thereof. This agent can also be administered in combination with a pegylated interferon and ribavirin. The invention further relates to a pharmaceutical composition for the treatment of a viral hepatitis C. This invention solves the problem of providing a novel agent, which is effective in the treatment of a viral hepatitis C and makes it possible to produce a sustained virologic response.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: May 31, 2016
    Assignee: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES”
    Inventors: Vladimir Evgenievich Nebolsin, Dmitry Yurievich Konstantinov, Larisa Leonidovna Popova, Elena Alekseevna Strebkova, Petr Grigorievich Deryabin
  • Patent number: 9295649
    Abstract: The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: March 29, 2016
    Assignee: BIND Therapeutics, Inc.
    Inventors: Mir Mukkaram Ali, Abhimanyu Sabnis, David Dewitt, Greg Troiano, James Wright, Maria Figueiredo, Michael Figa, Christina Van Geen Hoven, Young-Ho Song, Jason Auer, Tarikh Christopher Campbell
  • Patent number: 9193690
    Abstract: Disclosed herein is a pharmaceutical composition comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol and methods of using the composition to treat chronic pain.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: November 24, 2015
    Assignee: Allergan, Inc.
    Inventor: Daniel W. Gil
  • Patent number: 9150514
    Abstract: The invention is directed to methods for treating hypertension or heart failure using compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. In particular embodiments, the invention uses compounds having formula IIIa, IVa, Va: These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: October 6, 2015
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul Allegretti, Seok-Ki Choi, Roland Gendron, Paul R. Fatheree, Keith Jendza, Robert Murray McKinnell, Darren McMurtrie, Brooke Olson